In addition, nintedanib was more effective than sunitinib in the GIST‐T1‐T670I and GIST‐5R cell lines, which are both imatinib resistant and harbour gatekeeper T670I and Δ560–578 KIT mutations. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.